DexCom (DXCM) is under the spotlight after several class action lawsuits were filed claiming the company made unauthorized changes to its G6 and G7 glucose monitoring devices. These changes could ...
DexCom reports quarterly earnings of 45 cents per share, which beat the analyst consensus estimate of 43 cents. Quarterly revenue comes in at $994.2 million, which beat the analyst consensus estimate ...
Predictions of a sales-growth slowdown sent DexCom stock tumbling this summer. Management predicted third-quarter sales would rise by just 1% to 3% year over year. Two of DexCom's top competitors ...
DexCom is a leader in the continuous glucose monitoring (CGM) systems market. They aren't the only kinds of devices that help diabetes patients keep track of their blood glucose levels -- a necessary ...
DexCom , Inc. (NASDAQ:DXCM), a leader in continuous glucose monitoring (CGM) systems for diabetes management with a market ...
DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling being ~$7.5bn in peak annual revenues. Despite positive Q4 2024 results, DexCom's stock is fairly valued, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results